Programming Grants to Accompany NEH on the Road Exhibitions

Deadline :  4-6-2018

Funding Opportunity :  PAR-15-289

CFDA :  93.394|000000

Agency :  Department of Health and Human Services

Contact :  NIH OER Webmaster
This email address is being protected from spambots. You need JavaScript enabled to view it.

                This email address is being protected from spambots. You need JavaScript enabled to view it.

Eligibility :  State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Native American Tribal Governments (Federally recognized)
Public Housing Authorities/Indian Housing Authorities
Native American Tribal Organizations (other than Federally recognized tribal governments)
Nonprofits Having a 501 (c) (3) Status with the IRS (other than institutions of higher education)
Nonprofits that do not have a 501 (c) (3) status with the IRS (other than institutions of higher education)
Private institutions of higher education
For-profit organizations other than small business
Small businesses
Others

Details :  
This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions. This initiative addresses one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The PCDC is intended to support research for the development and testing of new molecular and imaging biomarkers for identifying patients at high risk for PDAC (because of genetic factors or the presence of precursor lesions) who could be candidates for early intervention. The research will be conducted by individual multi-disciplinary research teams, hereafter called Units. The Units will undertake studies on the following areas: identification and testing of biomarkers measurable in bodily fluids for early detection of PDAC or its precursor lesions; determine which pancreatic cysts are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; conduct biomarker validation studies; and collect longitudinal biospecimens for the establishment of a biorepository. All Units are expected to participate in collaborative activities with other Units and share ideas, specimens and data within the Consortium.